Dr. Laura Witte
Malignant Hyperthermia is a rare, life-threatening disorder induced by pharmacologic agents. It manifests as an exaggerated metabolic response to volatile anesthetics. An increase in end-tidal CO2 is one of the first indications of malignant hyperthermia. The effective management of malignant hyperthermia is Dantrolene sodium. Rapid recognition of malignant hyperthermia and availability of Dantrolene sodium in anesthesia settings is necessary for patient survival. This review will discuss clinical features and therapeutic interventions along with genetic association.
Phillips MPAS, PA-C, R.T.(R)(ARRT) AA. Malignant Hyperthermia: A Review of Clinical Features and Therapeutic Interventions. Lynchburg Journal of Medical Science. 2022; 4(3).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.